Patrick J. Haley - Dec 12, 2023 Form 4 Insider Report for EXELIXIS, INC. (EXEL)

Role
EVP, Commercial
Signature
/s/ Nina Ayer, Attorney in Fact
Stock symbol
EXEL
Transactions as of
Dec 12, 2023
Transactions value $
-$671,353
Form type
4
Date filed
12/14/2023, 07:56 PM
Previous filing
Sep 8, 2023
Next filing
Jan 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXEL Common Stock Sale -$318K -14.1K -4.4% $22.50 308K Dec 12, 2023 Direct F1, F2, F3
transaction EXEL Common Stock Options Exercise $815K +50K +16.25% $16.29 358K Dec 14, 2023 Direct F3
transaction EXEL Common Stock Sale -$1.17M -50K -13.98% $23.35 308K Dec 14, 2023 Direct F1, F3, F4
holding EXEL Common Stock 23.5K Dec 12, 2023 By spouse
holding EXEL Common Stock 10.6K Dec 12, 2023 By 401(k) F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EXEL Option (right to buy) Options Exercise $0 -50K -100% $0.00* 0 Dec 14, 2023 Common Stock 50K $16.29 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2023.
F2 Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.50 to $22.52. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
F3 Includes 200,242 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F4 Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.01 to $23.66. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.
F5 Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of December 11, 2023.
F6 The option, representing the right to purchase a total of 50,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 19, 2020.